Scholar Rock Holding Corporation

SRRK Healthcare Biotechnology

Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.

EPS
+14.3%
Free cash flow
+8.88%
Total debt
+294.3%

Quarter to June 2026, against a year earlier

46.94 1.44 +3.16%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
−7.3×
Dividend yield
—
F-score
3/9
Altman Z
1.14
Beneish M
n/a
Dividend safety
n/a

Scholar Rock Holding Corporation (SRRK) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Scholar Rock Holding Corporation (SRRK) trades at a P/S ratio of 130×. Over the past ten years it has ranged from 0.0× (December 2019) to 166× (August 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2022 12.1× (75.09%)
FY2021 48.5× (49.95%)
FY2020 96.8× 446.72%
FY2019 17.7× —
FY2016 0.0× —

Quarterly newest first

Period P/S ratio Change
Mar 2022 10.2× (78.94%)
Dec 2021 48.5× (27.17%)
Sep 2021 66.5× (0.71%)
Jun 2021 67.0× (45.16%)
9 more quarters

Against its own ten years

Low 0.0× High 166×
Ten-year median 22.4×
Current reading's percentile 93

P/S ratio against peers

Company P/S ratio
BLTE Belite Bio, Inc. Sponsored ADR compare n/m
ERAS Erasca, Inc. compare n/m
MANE Veradermics Incorporated compare n/m
IMVT Immunovant, Inc. compare n/m
KOD Kodiak Sciences Inc. compare n/m
PTCT PTC Therapeutics, Inc. compare 4.8×
SRRK Scholar Rock Holding Corporation 126×
COGT Cogent Biosciences, Inc. compare 220×
CGON CG Oncology, Inc. compare 919×
Biotechnology industry median 9.2×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on SRRK